Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial

Journal of Clinical Psychopharmacology

Volumn 23, Issue 5, 2003, Pages 509-513

  Avila, Asunción ^a,b   Cardona, Xavier ^a   Martin Baranera, Montserrat ^a   Maho, Plácida ^a   Sastre, Francesc ^a   Bello, Juan ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b 08906 L'Hospitalet de Llobregat ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; FLUOXETINE; NEFAZODONE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ASTHENIA; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DOPAMINE RELEASE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PILOT STUDY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREMOR; VERTIGO;

AGED; ANALYSIS OF VARIANCE; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TRIAZOLES;

EID: 0141705744     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000088908.24613.db     Document Type: Article

References (17)

1. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry. 1999;14:711-718.
2. Laitinen L. Desipramine in the treatment of Parkinson's disease. Acta Neurol Scand. 1969;45:109-113.
3. Andersen J, Aabro E, Gulman N, et al. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand. 1980;62:210-219.
4. Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord. 1995;10:355-357.
5. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 1997;12:756-759.
6. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord. 2000;15:986-989.
7. Meco G, Bonifati V, Fabrizio E, et al. Worsening of parkinsonism with fluvoxamine: two cases. Hum Psychopharmacol. 1994;9:439-441.
8. Jiménez-Jiménez FJ, Tejeiro J, Martinez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology. 1994;44:2406.
9. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull. 1990;26:311-315.
10. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
11. Guy W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual. Rockville: National Institute Mental Health; 1976.
12. Lingjaerd O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. Acta Psychiatr Scand. 1987;76(suppl 334):1-100.
13. Fahn S, Elston RL and members of the UPDRS development committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol. 2. New York: MacMillan; 1987:153-163.
14. Abnormal Involuntary Movements Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual. Rockville, MD: US Department of Health, Education and Welfare; 1976:534-537.
15. Stahl SM. Basic psychopharmacology of antidepressants: Part 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59(suppl 4):5-14.
16. Stahl SM. Antipsychotic Agents. In: Essential Psychopharmacology. Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge University Press; 2000;11:401-458.
17. Dewey SL, Smith Gs, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995;15:821-829.